Adial Pharmaceuticals, Inc (ADIL) financial statements (2020 and earlier)
Company profile
| Business Address |
1180 SEMINOLE TRAIL CHARLOTTESVILLE, VA 22902 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 6,777 | 3,869 | ||
| Cash and cash equivalents | 6,777 | 3,869 | ||
| Prepaid expense | 831 | 506 | ||
| Intangible current assets | 1 | |||
| Other undisclosed current assets | 64 | 318 | ||
| Total current assets: | 7,673 | 4,693 | ||
| Noncurrent Assets | ||||
| Other noncurrent assets | 6 | 7 | ||
| Total noncurrent assets: | 6 | 7 | ||
| TOTAL ASSETS: | 7,680 | 4,699 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities, including: | 539 | 258 | ||
| Accounts payable | 190 | |||
| Accrued liabilities | 349 | |||
| Other undisclosed accounts payable and accrued liabilities | 258 | |||
| Total current liabilities: | 539 | 258 | ||
| Noncurrent Liabilities | ||||
| Total liabilities: | 539 | 258 | ||
| Stockholders' equity | ||||
| Stockholders' equity attributable to parent | 7,141 | 4,441 | ||
| Common stock | 10 | 7 | ||
| Additional paid in capital | 27,757 | 16,470 | ||
| Accumulated deficit | (20,627) | (12,035) | ||
| Total stockholders' equity: | 7,141 | 4,441 | ||
| TOTAL LIABILITIES AND EQUITY: | 7,680 | 4,699 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|
| Gross profit: | (1,167) | ||
| Operating expenses | (8,245) | (6,987) | |
| Other undisclosed operating income | 1,167 | ||
| Operating loss: | (8,245) | (6,987) | |
| Nonoperating expense | (347) | (4,644) | |
| Investment income, nonoperating | 95 | 7 | |
| Interest and debt expense | (5) | ||
| Loss from continuing operations before equity method investments, income taxes: | (8,591) | (11,636) | |
| Other undisclosed income from continuing operations before income taxes | 5 | ||
| Loss from continuing operations before income taxes: | (8,591) | (11,631) | |
| Income tax expense | (14,246) | ||
| Loss before gain (loss) on sale of properties: | (22,838) | (11,631) | |
| Other undisclosed net income | 14,246 | ||
| Net loss available to common stockholders, diluted: | (8,591) | (11,631) | |
Comprehensive Income ($ in thousands)
| 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|
| Net loss: | (8,591) | (11,631) | |
| Comprehensive loss, net of tax, attributable to parent: | (8,591) | (11,631) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.